<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1755">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138315</url>
  </required_header>
  <id_info>
    <org_study_id>AEM</org_study_id>
    <nct_id>NCT05138315</nct_id>
  </id_info>
  <brief_title>Quantification of Metamorphopsia in Patients With Epiretinal Membranes</brief_title>
  <official_title>Quantification of Metamorphopsia Using the Alleye App Compared to the M-chart in Patients With Epiretinal Membranes a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vienna Institute for Research in Ocular Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to examine metamorphopsia before and 3 months after vitrectomy with&#xD;
      membrane peeling among patients with idiopathic epiretinal membranes. Therefore, the&#xD;
      correlation between the Alleye App and the M-chart test before and after ERM surgery and the&#xD;
      associations of OCT biomarkers to postsurgical changes in metamorphopsia scores will be&#xD;
      examined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epiretinal membranes are common disorders leading to visual loss and metamorphopsia in later&#xD;
      stages. In most cases they are idiopathic with no identifiable cause (iERM). ERM can be&#xD;
      visualized with optical coherence tomography (OCT) and can cause metamorphopsia, usually&#xD;
      diagnosed with the Amsler grid or metamorphopsia chart (M-chart), which have influence on&#xD;
      vision. ERM are surgically treated by vitrectomy and membrane peeling, however, postoperative&#xD;
      visual acuity and quality of vision are difficult to predict. Quality of vision is highly&#xD;
      dependent on metamorphopsia which can be an overlooked symptom. Thus, detailed examinations&#xD;
      using M-charts prior to surgery can help to quantify the degree of metamorphopsia and might&#xD;
      predict the potential benefit of the surgery. Recently, home monitoring tests for&#xD;
      metamorphopsia using handheld mobile devices are becoming increasingly important. The Alleye&#xD;
      App is one of two m-health applications with FDA approval, that is already in use for&#xD;
      monitoring the progression of metamorphopsia in other retinal diseases such as age-related&#xD;
      macular degeneration (AMD). It has yet to be evaluated for ERM. Aim of this study is to&#xD;
      examine the correlation between the Alleye App and the M-chart test before and after ERM&#xD;
      surgery and the associations of OCT biomarkers to postsurgical changes in metamorphopsia&#xD;
      scores.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alleye App Score</measure>
    <time_frame>5 minutes</time_frame>
    <description>The Alleye App measures the degree of metamorphopsia, the range of the Alleye App Score: 0 to 100 points, with 100 being the best achievable result, while lower values are associated with increasing degree of metamorphopsia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>M-chart Scores (horizontal and vertical)</measure>
    <time_frame>5 minutes</time_frame>
    <description>The M-charts measure the degree of horizontal and vertical metamorphopsia, the range of M-charts: 0 to 2.0, with higher values indicating a higher degree of metamorphopsia</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alleye App and M-chart examinations will be performed pre- and postsurgically.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Metamorphopsia quantification</intervention_name>
    <description>Alleye App and M.chart examinations will be performed pre- and postsurgically.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic ERM&#xD;
&#xD;
          -  Sheduled surgery (vitrectomy with membrane peeling)&#xD;
&#xD;
          -  Age 18 and older&#xD;
&#xD;
          -  Written informed consent for participation in the study&#xD;
&#xD;
          -  Metamorphopsia detected by the Amsler grid&#xD;
&#xD;
          -  BCVA â‰¥ 0,1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary ERM due to retinal tears, retinal detachment, retinal vascular diseases and&#xD;
             uveitis&#xD;
&#xD;
          -  Other macular disorders including AMD&#xD;
&#xD;
          -  Previous intraocular surgery except for uncomplicated cataract surgery&#xD;
&#xD;
          -  Pregnancy (pregnancy test will be performed in women of reproductive age)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Findl, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>head of department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver Findl, Prof.</last_name>
    <phone>+43 1 91021 84611</phone>
    <email>oliver.findl@oegk.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Leisser, MD</last_name>
    <phone>+43 1 91021 84611</phone>
    <email>christoph.leisser@oegk.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Findl, MD, MBA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Prof., MD, MBA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

